A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone

NCT00000870 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

200

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Indinavir sulfate
DRUG: Lamivudine
DRUG: Stavudine
DRUG: Zidovudine
DRUG: Didanosine
DRUG: Aldesleukin

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)